Meta-analysis of Shugan Jieyu Capsule for depression in patients with coronary heart disease

Abstract

Introduction: Shugan Jieyu Capsule (SGJYC) has been prescribed to treat primary and secondary depression; however, whether it can benefit depression of patients with coronary heart disease (CHD) remains controversial. This meta-analysis aimed to evaluate the efficacy and safety of SGJYC in treating depression in patients with CHD. Patient concerns: A total of 644 CHD patients with depression were selected from China National Knowledge Infrastructure, Wanfang, China Biomedical Database, MEDLINE, the Cochrane library from their inceptions until June, 2021. Diagnosis: All patients with CHD or coronary artery disease were confirmed to suffer from depression based on recognized criteria. Intervention: Patients were assigned randomly to receive SGJYC-based regimens or conventional antidepressants alone. Outcomes: Meta-analysis of 6 studies showed that antidepressants (MD, 2.12; 95% confidence interval [CI], 0.73~3.50) or sertraline (MD, 2.15; 95%CI, 0.61~3.68) significantly alleviated depression level compared to SGJYC; however, SGJYC plus antihypertensive drugs (AHD) (MD, −8.33; 95%CI, −13.90 ~ −2.75) significantly improved depression symptoms compared to AHD. A significant difference in risk of adverse cardiac events (risk ratios [RR], 2.72; 95%CI, 1.07~6.94) between SGJYC and sertraline was detected in patients with simple CHD. Conclusions: SGJYC has a poor effect on depressive symptoms, and the effect of combination with AHD is better than AHD but its efficacy and cardiac safety are inferior to antidepressants.

Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis

“…et al, 2016 ; Li SSYM. et al, 2016 ; Jin et al, 2017 ; Lai and Yi, 2017 ; Li and Guo, 2017 ; Jia et al, 2019 ; Li and Wang, 2019 ; Li et al, 2003 ; Li and Wang, 2004 ; Li, 2007 ; Li and Qian, 2007 ; Liu et al, 2007 ; Li and Tian, 2008 ; Li and Dong, 2009 ; Li et al, 2010 ; Liu and Tan, 2010 ; Lin et al, 2011 ; Liu and Zhang, 2012 ; Li and Luo, 2013 ; Li et al, 2014 ; Li and Wang, 2015 ; Liu and Wang, 2015 ; Liu and Wang, 2017 ; Li et al, 2018 ; Lin and Han, 2019 ; Liu and Wang, 2019 ; Li et al, 2020 ; Luo and Zhao, 2006 ; Meng et al, 2008 ; Mao and Li, 2010 ; Ran et al, 2010 ; Meng and Li, 2011 ; Qiu and Zhu, 2011 ; Qu et al, 2011 ; Mao and Li, 2016 ; Meng et al, 2016 ; Nie et al, 2016 ; Qin and Tang, 2016 ; Ma and Ye, 2017 ; Qi et al, 2017 ; Ren, 2017 ; Min CX and Li, 2018 ; Lu and Li, 2019 ; Luo et al, 2019 ; Lu and Xin, 2020 ; Luo and Wu, 2021 ; Lu and Sun, 2022 ; Shen and Zhao, 2004 ; Tao and Li, 2006 ; Shi and Zeng, 2008 ; Ta et al, 2008 ; Tang and Wang, 2009 ; Shao and Zhao, 2011 ; Wang and Wang, 2011 ; Sun and Li, 2012 ; Sun and Zhou, 2012 ; Tao and Yin, 2012 ; Ren and Li, 2015 ;…”

Research Status and Trends of Traditional Chinese Medicine Therapeutic Formulae for Coronary Heart Disease Scientometrics Research

“…The representative formula of this category is "Shugan jieyu capsule" (SGJYC), and some scholars have evaluated the efficacy and safety of SGJYC and found that the efficacy of depressive symptoms was poorer than that on the combination of anti-hypertensive drugs (AHD), but its efficacy and cardiac safety were inferior to antidepressants. 36 Transforming phlegm and dispelling blood stasis. This type of formula is "Danlou tablet", which is mainly applied to patients with phlegm obstruction syndrome, and the main constituent drugs are Dan Shen, Gua Lou, Red Peony, Allium sativum and other drugs.…”